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Abstract: Primarily due to recent advances of detection techniques, microchimerism (the proportion
of minor variant population is below 1%) has recently gained increasing attention in the field of
transplantation. Availability of polymorphic markers, such as deletion insertion or single nucleotide
polymorphisms along with a vast array of high sensitivity detection techniques, allow the accurate
detection of small quantities of donor- or recipient-related materials. This diagnostic information can
improve monitoring of allograft injuries in solid organ transplantations (SOT) as well as facilitate early
detection of relapse in allogeneic hematopoietic stem cell transplantation (allo-HSCT). In the present
review, genetic marker and detection platform options applicable for microchimerism detection are
discussed. Furthermore, current results of relevant clinical studies in the context of microchimerism
and SOT or allo-HSCT respectively are also summarized.
Keywords: microchimerism; solid organ transplantation; hematopoietic stem cell transplantation;
genetic marker; single nucleotide polymorphism; deletion/insertion polymorphism
1. Introduction
Co-existence of genetically distinct/discordant tissues or cells is termed chimerism after the
well-known Greek fusion creature. Based on the extent of the variant population, microchimerism is
usually mentioned as a subgroup of chimerism in which the proportion of foreign cells or tissue does not
exceed 1%. This proportion can readily be estimated in the circulation while quantitative comparison
of major and minor populations is more challenging in cases of scattered cells or transplanted tissue.
Based on origin, naturally occurring and therapy related microchimerism can be distinguished.
Naturally occurring microchimerism refers to the bidirectional interaction between the genetically
distinct mother and fetus(es) resulting in the long-lasting presence of small numbers (well below
1%) of fetal cells in the mother and vice versa. The interesting immunological consequences of these
coexistences have recently been elegantly reviewed [1] and is not discussed in the present review.
The term therapy related microchimerism describes situations primarily related to transplantations
and occasionally transfusions. Subsequent to solid organ transplantations (SOT) a well-defined organ
coexists with the recipient which rarely involves mixture of cells. In contrast, variable recipient–donor
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cell ratios are characteristic for patients treated by allogeneic hematopoietic stem cell transplantation
(allo-HSCT).
The quantitative detection of chimerism in the circulation might serve as a biomarker with clinical
relevance, which is based on polymorphic genetic structures (markers) similarly to those applied in
forensic medicine for person identification. Large scale population studies such as the 1000 Genome
Project characterized and classified millions of human variants in different populations allowing the
identification of appropriate markers with high heterozygosity rate and discriminatory power. In the
last decade, the development of highly sensitive, quantitative and accurate methods, e.g., digital
PCR or next generation sequencing (NGS) enabled the precise quantitation of unprecedently low
level molecular variants. As a result, the clinical application of these innovative technologies for
microchimerism detection has started to enter the daily practice. In general, the paradigm of marker
selection in transplantation dictates an allele choice as a marker that is not present in the dominant cell
or molecule population: after SOT the donor should be marker positive and the recipient negative,
while after allo-HSCT the opposite relationship is required.
Chimerism could be investigated on cellular or on cfDNA level. The latter consists mainly of small
sized (around 150 base-pairs) double-stranded DNA fragments resulting from apoptosis, necrosis,
immune-mediated cell damage, or release of nuclear DNA into the circulation predominantly from
hematopoietic cells [2]. In the circulation, these fragments have a short half-life of approximately 1.5 h
due to rapid hepatic and renal clearance [3].
In the present paper, we provide an extensive review of the available information about
microchimerism in the context of various forms of transplantation and transplantation-related advanced
therapies with a special emphasis on the available markers and the multitude of detection platforms in
this high sensitivity range.
2. Polymorphic Genetic Markers Applicable for Chimerism Detection
2.1. Short Tandem Repeats (STR)
So far, more than 700,000 STRs (short tandem repeats) are characterized in human genome, for the
most part they are considered as ‘junk DNA’, however some of them are located in protein coding
region and associated with genetic disorders [4–6]. STRs—also referred to as microsatellites—consist of
2 to 6 nucleotide tandem repeats distributed throughout the genome. These loci are highly polymorphic
and different alleles are determined by the varying number of nucleotide repeats (3 to 51 repeats).
Short tandem repeat (STR) analysis is a standard and approved method applied in forensics and in
hematopoietic chimerism quantification after allo-HSCT [7]. Nearly 100% informativity can be reached
with a panel of 12–16 STR markers (Core STR Loci), including loci on sex chromosomes, that allow
differentiation between individuals [8–10]. The major advantage of STRs is its multiallelic (up to
16 distinct variants) nature and consequential high informativity rate, which allows its application in
all donor–recipient pairs or furthermore in transplants with multiple donors.
2.2. Single Nucleotide Polymorphism (SNP)
These represent the most frequently observed variations in the human genome, around 1/1000
basepairs [11]. In an average individual there are ten times more SNPs to be found compared to deletion
insertion polymorphisms (DIP). Since the discrimination power of biallelic variants is lower compared to
STRs, more loci have to be simultaneously tested to reach an acceptable informativity range. Reportedly,
already seven SNP markers can be highly discriminative (97% informativity) in HLA-identical sibling
pairs [12]. On the other hand, a study using a combined panel of markers described only 80% overall
informativity with six SNPs, two null alleles (SRY, RhD) and two DIPs [13]. Almeida et al. calculated
81% informativity for eight biallelic SNP markers investigating 88 patient/donor pairs [14]. Fredriksson
et al. used an array consisting of 51 SNPs to reach 100% informativity [15]. In the context of SOT,
SNP assays have widely been used to detect donor-derived cfDNA (dd-cfDNA) amount in plasma
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with an early, method-focused application using digital PCR (see Section 3) in small sets of liver,
kidney, and heart transplanted patients [16]. This approach was further developed and characterized
in detail by Grskovic et al. [17] in the form of a commercial assay (CareDx, Brisbane, CA, USA)
employing 266 SNPs and NGS (see Section 3) with a convincing validation in a large group of heart
transplanted patients. The technical advances made possible a highly sophisticated approach of
massive multiplexing allowing the utilization of more than 13,000 SNP markers [18], as well as an
alternative commercial, NGS-based assay [19]. The enormous amount of information obtained from
massively parallel SNP-typing by NGS also allows donor–recipient distinction in the absence of
pre-testing potentially further simplifying the routine application [20,21].
2.3. Deletion Insertion Polymorphisms (DIP)
DIPs or INDELs are relatively short (up to about 50 bases in length), frequently biallelic variations
located in non-coding regions of the genome displaying a lower mutation rate compared to STRs. As a
consequence of the emergence of NGS technology and advanced software algorithms, the number of
identified and characterized DIPs is rapidly increasing [22–24]. While searching the world’s largest
public human variation database (dbSNP Build 152) and applying a filter for intergenic human DIPs,
not restrictive to the length of the polymorphism, nearly 9 million hits are found. Biallelic DIPs
are suitable and reliable markers which are now commonly used for monitoring donor–recipient
tissue proportions in transplantation as well in person-identification in forensic medicine [25,26].
To monitor chimerism after allo-HSCT, Alizadeh et al. utilized 19 specific markers located on 9 different
chromosomes reaching an informativity level of approximately 90%. This approach has been later
validated by others [27–29]. A further study extended this system with two additional DIP markers
and optimized their assay for SYBR green with a possible discrimination of 94% [30]. Subsequently,
Pereira et al. developed a DIP-based multiplex assay for human identification, which uses 38 biallelic
markers characterized by high heterozygosity rates in distinct population groups, reaching an
approximate informativity of 100% [26]. As an alternative to hybridization probes, Goh et al. analyzed
dd-cfDNA after liver transplantation by targeting DIPs by the amplification primers themselves [31].
The successful application of as few as 10 DIPs along with digital PCR for the detection of dd-cfDNA
in a small cohort of heart transplanted patients published as a less resource demanding approach [32].
Besides these publicly available marker collections, a large selection of commercial kits are also
available, indicating the importance of the approach [33–37]. Combinations of DIPs and SNPs (a total
of 26 markers) were also tested with a genotype identification rate of 97% [38] and with another
set (a total of 29 markers) resulting an informativity of 97% [39]. The major advantage of DIPs is
the potential to use these markers in high sensitivity assay such as quantitative PCR or digital PCR
(see Section 3) to reliably detect microchimerism equally important in SOT and allo-HSCT.
2.4. Other Special Markers Used in Monitoring
Evidently, application of sex determining markers (e.g., SRY, AMELY, DFFRY, SMCY) are
only useful and informative in sex-mismatched transplanted patients both in allo-HSCT and SOT.
The amelogenin gene has an X and Y linked variant (AMELY and AMELX). The basis of variability
in this case is a 6-basepair-long deletion segment found in X chromosome (AMELX). Utilization of
Y specific markers, e.g., SRY, rely on the detection of a gene exclusively located on chromosome Y.
Both sex-specific markers are informative in allo-HSCT when the recipient is a male and the donor is
a female [2,40,41], while in SOT the expected situation is exactly the opposite. Similarly, RhD blood
group (which is a 58 kilobase-long DIP, i.e., RhD-negativity is equal to a complete deletion) is also
a straightforward choice in monitoring RhD positive allo-HSCT patients with RhD negative donor.
The opposite is applicable in SOT (an RhD negative recipient with an RhD positive donor) [13,42].
Besides these, another informative marker set is the HLA which information for both donor and
recipient is readily available prior to transplantation. Disparate HLA-markers were successfully used
to detect elevations in dd-cfDNA plasma concentrations associated with lung transplant complications.
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However, the major obstacle of the widespread use of this approach may be the need for the practically
individual detection probe design depending on the actual HLA-disparities between the donor and
recipient [43].
2.5. Guidelines for Marker Selection to Detect Clinical Chimerism
An ideal marker should be located in non-coding region ruling out the chance it is linked to
genetic diseases, plays a role as genetic susceptibility factor or influences certain disease progression
or response to therapy. It should be biallelic, differing by at least 2 basepairs, with a minimum allele
frequency of at least 0.25 and a high level of heterozygosity (>0.4). Their chromosomal localization
should be as distant as possible or on different chromosomes and they should also be located in
sufficient distance from repetitive regions [25,26]. When designing SNPs as markers, loci with C/T and
G/A polymorphisms are preferred to achieve more specific allele discrimination [38]. The recommended
number of markers allowing sufficient informativity (>95%) for STR varies between 12 and 16, while for
DIPs and SNPs a larger set is required (up to 52 markers). For follow-up diagnostics, more than
one marker is recommended to avoid false negative results e.g., due to allele-dropout during the
polymerase chain reaction (PCR) or due to the deletion of chromosomal region of the chosen marker in
hematological malignancies [9,37]. Loss of chromosome Y was observed not only in hematological
malignancies, but also in aging healthy males.
3. Comparison of Microchimerism Detection Techniques
As allo-HSCT became widespread, an imperative need arose to repeatedly discriminate recipient
and donor cells in the circulation after allo-HSCT for which various techniques have been developed.
Initially, these approaches had limited sensitivity in the range of 10% recipient cells allowing only
to characterize chimerism and not microchimerism. The most commonly used chimerism-detection
methods in this time period were XY fluorescence in-situ hybridization and polymerase chain reaction
(PCR) based amplification of variable number of tandem repeats (VNTR) or short tandem repeats
(STR). The PCR-based technologies more recently predominantly use fragment analyses (FA) making
it possible reach a sensitivity range of 1% still unsuitable for the reliable detection of microchimerism
(see the detailed review of Clark et al. [9]). Systematic comparison of three most widely used
microchimerism detection technologies with reference to the gold-standard chimerism detection
technique, fragment analysis is shown in Table 1.
Table 1. Comparison of chimerism/microchimerism laboratory detection techniques.
Technique Fragment Analysis # qPCR dPCR NGS
Targeted Genetic Variant limited number ofmultiallelic markers (STR)
limited number of biallelic
markers (SNP, DIP)
limited number of biallelic
markers (SNP, DIP)
unlimited number of
biallelic markers (SNP)
Limit of Detection >1% 1–0.01% 1–0.01% 1–0.01%
TAT short shortest short longer
Equipment Cost considerable relatively lower considerable considerable
Allo-HSCT Marker
number * 3 2 2 not relevant
Advantages
gold standard #;
widespread application;
large experience
high sensitivity;
short TAT
high sensitivity;
high precision
high number. of SNPs;
simultaneous chimerism
& MRD
Technical Limitations
stutter peak; preferential
amplification;
semi-quantitative
labor-intensive
optimization;
calibration curve;
PCR inhibitors; duplicate
low no. of variants
dependent on DNA
concentration;
low number of variants
infrastructure costs;
longer TAT;
bioinformatics;
lack of standardization
# Fragment analysis has been used for the longest time albeit due to its low sensitivity it is not suitable for
microchimerism detection. * Minimum number of markers for allo-HSCT follow-up. Abbreviations: dPCR: digital
PCR; DIP: deletion insertion polymorphism; HSCT: hematopoietic stem cell transplantation; MRD: measurable
residual disease; NGS: next generation sequencing; qPCR: real time quantitative PCR; SNP: single nucleotide
polymorphism; STR: short tandem repeat; TAT: turnaround time.
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3.1. Real-Time Quantitative PCR (qPCR)
To increase the sensitivity of chimerism monitoring in transplanted patients, several studies
proposed real-time quantitative PCR (qPCR) method to detect single nucleotide polymorphisms
(SNPs) or short deletions/insertions (DIP). QPCR allows 0.1% sensitivity quantification of the minor
genotype [12,25,28,37,38,44]. The vast majority of studies employ TaqMan technology requiring a
hybridization probe labeled with two different fluorescent dyes: a reporter (FAM), and a quencher
(TAMRA). When the probe is intact, fluorescent energy transfer occurs and the reporter fluorescence is
readily absorbed by the quencher. In case of precise hybridization of the probe to its target, during the
extension phase of the PCR cycle, the 5’-3’ exonuclease activity of the DNA-polymerase cleaves the
TaqMan probe and releases the reporter dye, resulting in an increase of the reporter dye fluorescent
signal [45]. Probes can be labeled with alternative, distinguishable reporter dyes allowing duplexing
in a single reaction. The disadvantage of the qPCR technique is the requirement of labor-intensive
optimization and the need for replicates (duplicates, triplicates) in each run for each target to provide
the most accurate result [12,25].
3.2. Digital PCR (dPCR)
Digital PCR has initially been used to quantify low-copy number fetal DNA in maternal plasma [46].
This innovative approach is based on partitioning of the PCR in multiple nanoliter chambers or
droplets, and after the amplification, each chamber/droplet is counted positive or negative for a specific
polymorphism [47]. With increasing the number of partitions (e.g., performing replicates), sensitivity
of the test can be improved. A further innovation of this technique, droplet digital PCR (ddPCR),
is easily automated and does not require a dedicated PCR machine. In contrast to qPCR which allows a
real time approach, dPCR is an end-point assay with the determination of the positive droplet fraction
and Poisson statistics calculating the absolute number of starting copies making calibration curves
unnecessary [47,48]. Due to the simultaneous presence of reference amplification in each reaction
during dPCR, as well as a consequence of unprecedented precision, replicates are not needed in cases
with target concentrations above the limit of detection. This method is less sensitive to inhibitors
than fragment analysis or qPCR. The technique is highly suitable for the detection of rare events in
the presence of high background. Performing the quality control test on artificial chimerism mixture
samples Mika et al. found high correlation between the estimated and the observed percentage values
for two discriminating markers. The standard deviation of the four-time repeated measurements of a
dilution series with one discriminating marker ranged from 1.8% to 3.7%. Comparing dPCR to the
‘gold-standard’ STR by fragment analyzes indicated good agreement between these two techniques in
the detection range of 83–100% of donor chimerism [49]. The limit of detection of dPCR was estimated
to be as low as 0.008% allowing the reliable determination of microchimerism. Additionally, assay
precision was acceptable also in ranges of microchimerism, with a variation coefficient of 16% at 1:999
dilution [36]. The dPCR technique proved to be more sensitive in detection of relapse after allo-HSCT
compared to qPCR [35]. Similarly to allo-HSCT, dPCR has also been widely used in the context of
SOT to detect dd-cfDNA in combination with DIPs [32,50], SNPs [3], copy number variations [51],
or HLA-disparities [17,18,43,52].
3.3. Next Generation Sequencing (NGS)
Next generation sequencing (NGS) is a massively parallel or deep sequencing, where millions
of small fragments of DNA are sequenced in parallel affording an unprecedentedly high sensitivity.
Sequenced fragments are pieced together by mapping individual reads to the human reference genome
by bioinformatic tools. Several different NGS platforms exist with different chemistries and techniques.
NGS can be used to sequence individual genes, targeting the whole exome or even the entire genome [53].
This technique is more sensitive than fragment analysis (0.01% to 1% vs. >1%). Compared to STR
by fragment analyzes, NGS showed an excellent correlation [54,55]. The unprecedented capacity of
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NGS allows the simultaneous typing of large marker sets, predominantly SNPs, which has frequently
been used to perform dd-cfDNA detection in various SOT settings. The large number of SNP markers
applied clearly gives an unprecedented opportunity to distinguish two genomes, even in cases of
unavailable donor pre-transplant DNA sample or in cases with multiple numerical chromosomal
abnormalities. The main advantage of NGS is that it is applicable for simultaneous determination
of chimerism or microchimerism as well as multiple disease specific markers to detect measurable
residual disease (MRD). However, these techniques require substantial equipment background, reagent
cost, trained bioinformatics expertise, standardization, and currently they are not always characterized
with sufficiently short turn-around time to readily influence clinical decision making. The described
approaches belonged either to non-commercially designed systems [17,18,52] or to commercially
developed platform with an unequivocal intent of routine clinical application [56–58].
4. Sample Types, Preanalytics, and Isolation of Cell Free DNA
The volume of blood required for cfDNA analysis is usually between 6 and 10 mL. Concentrations
in paired plasma and serum samples have revealed significantly higher cfDNA concentrations in serum
than in plasma [59]. This is due to leukocyte damage during clotting in the serum tube with a single
cell containing about 6 pg of DNA and adding up to 65 ng of DNA per mL of blood. As a consequence,
serum samples are not advised, instead plasma from anticoagulated (predominantly EDTA) blood
sample is used [60]. The use of tubes containing preservatives (PAXgene cfDNA tubes (Qiagen
PreAnalytiX GmbH, Düsseldorf, Germany), Roche/Ariosa cfDNA collection tubes (Roche Diagnostics
GmbH, Rotkreuz, Switzerland) and Streck BCT tubes (Streck Inc., Omaha, NE, USA, see [61]) to
prevent hemolysis and to reduce the degradation of cfDNA is becoming increasingly common practice
allowing an extended time to blood processing [62]. Interestingly, in the case of timely (up to 12 h
at room temperature) processing, there was no significant difference between cfDNA concentrations
in samples shipped in EDTA collection tubes versus samples shipped in cell-free DNATM blood
collection tubes [63,64]. Plasma preparation typically involves two rounds of centrifugation: a classical,
low speed centrifugation at 1000–2000 × g followed by a high speed centrifugation (16,000× g) [65].
In cases of a single centrifugation step at 800 × g, cfDNA concentrations were contaminated by genomic
DNA [66].
Two main types of cfDNA extraction systems have frequently been used: column-based systems
and magnetic beads systems. Studies comparing cfDNA extraction methods and kits revealed
substantial differences in total DNA yield [67]. cfDNA samples may withstand three freeze-thaw cycles
and storage at −20 ◦C. Storage time has no influence on specific sequences or mutations in cfDNA,
and mutations can be detected several years after freezing plasma samples, but cfDNA content is
decreasing with storage time, so quantification or characterization of cfDNA fragmentation, is preferred
within 3 months after the extraction procedure [68].
Quantitation of extracted cfDNA may be performed with several techniques such as
fluoro-spectroscopy, Qubit (Thermo Fisher Scientific Waltham, MA, US) fluorometry and qPCR.
In addition, quality control of isolated cfDNA can be performed by fragment analysis by capillary
electrophoresis. Based on fragment size, the relative amount of nucleosome-protected cfDNA fragments
with 140–160 base pairs can be compared to degradation-fragments with higher molecular weight
DNA [69,70]. Single-tube multiplex digital droplet PCR assays have also been described as alternative
approaches to measure amplifiable DNA concentrations and fragment size of small amounts of
cfDNA [62,71].
5. Role of Microchimerism in Solid Organ Transplantation
In the context of solid organ transplantations (SOT), the meaningful use of the term microchimerism
is only possible for cfDNA in the circulation since intact graft cells are unlikely to survive in blood.
Appearance of low amounts (usually less than 0.1%) of donor hematopoietic (passenger) cells in the
recipient’s circulation has been repeatedly observed after SOT and prompted speculations about a
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potential favorable role of these cells in graft acceptance. However, later clinical studies failed to
find consistent associations and this cell based microchimerism also showed large inter-individual
variations (see the excellent review by Eikmans et al. [1]).
After SOT, beside cells of donor origin, recently an increasing attention has turned towards
dd-cfDNA since upon immune-mediated, apoptotic, or necrotic cell damage, its amount increases.
This may then be translated to elevated levels of absolute amount or of relative proportions of
dd-cfDNA. Such changes may serve as sensitive surrogate biomarkers to monitor the health of the
transplanted organ (graft). This has outstanding significance as the overall frequency of graft related
post-SOT complications—i.e., rejection—immunosuppressive treatment mediated toxicity or infection
can reach 50% of all SOT cases [72]. For the timely alleviation of these complications (e.g., appropriate
adjustments of immunosuppressive therapies), systematic utilization of appropriate biomarkers
is essential. To this end, monitoring the health of the allograft by a diverse array of laboratory
parameters as well as therapeutic drug monitoring of immunosuppressive drugs has traditionally
been used to assist therapeutic decision making. In addition, monitoring and characterization of donor
specific antibodies (DSA) have recently gained increasing attention as the major causative factor of
antibody mediated rejection (ABMR). However, the direct translation of DSA-profile data into clinical
decision making has been challenging. It has been reported that up to 80% of patients with DSA
do not have ABMR and additional factors, such as type and strength of DSA, IgG subclass, and the
ability to bind complement, are important further determinants [73]. Besides the above-mentioned,
non-invasive monitoring options, graft biopsy procedures have traditionally represented the gold
standard for graft-damage evaluation which are invasive and costly, limiting their use in clinical
practice. A significant proportion of biopsies yield inadequate specimen and major complications
also occur relatively frequently. Furthermore, biopsy results are often compromised by expert reader
variance and can lead to delayed diagnosis of active rejection, after which irreversible organ damage
may have occurred [74].
Monitoring of dd-cfDNA in plasma as a non-invasive indicator of graft damage after SOT was
first suggested as early as in 1998 by the most outstanding expert of the field, Lo et al. [75] followed
by several early studies focusing on SOT [76–79]. At this stage, the techniques applied did not
readily allow the accurate detection of dd-cfDNA below 1% corresponding to true microchimerism.
In addition, restricted availability of suitable markers for donor vs. recipient distinction also hampered
cohort studies of larger consecutive series. With dramatic technical advancement (see Sections 2 and 3)
both, the sensitivity and the informative marker availability problem has been solved allowing the
completion of a number of cohort studies in various SOT settings. Studies on one hand attempted to
characterize the precise behavior of dd-cfDNA in the early phase of SOT as well as to establish reference
ranges documenting a sharp decline in the initial days and a proportion typically between 0.3% and
1.2% of total cfDNA in stable kidney transplant patients [16,19]. While for liver and transplants these
proportion values are somewhat higher [16]. On the other hand, the majority of studies addressed the
more exciting question namely how dd-cfDNA serves as a rejection biomarker. Several reviews have
summarized these studies [72,80–83]. Out of these, in their recent systematic review, Knight et al. [84]
published a large collection of relevant literature searches. However, no consistent distinction has
been made between conference abstracts and peer-reviewed in extenso publications making it difficult
to realize the number and extent of truly independent cohort studies. In addition, potential patient
overlaps between cohorts are also impossible to identify in this manner.
Thus, we performed a focused literature overview of exclusively peer-reviewed papers addressing
the potential role of plasma dd-cfDNA as a potential rejection marker in various SOT settings with an
inclusion criteria of total cohort size equaling or exceeding n = 50 for kidney or n = 20 for other solid
organs respectively. As shown in Table 2, a total of 15 studies met these criteria.
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Table 2. Selected cohort studies focusing on the potential role of dd-cfDNA in SOT of various organs.
ID Organ Year Author Center/Country StudyType
Study
Design * Total (n)
Rejection
(n)
1 kidney 2017 Bloom [56] Cedars-Sinai. LA, USA prosp biopsy 102 27
2 kidney 2018 Jordan [58] Cedars-Sinai. LA, USA retro biopsy 87 16
3 kidney 2018 Sigdel [18] UCSF, SF, USA retro consec 178 38
4 kidney 2019 Huang [57] Cedars-Sinai LA, USA prosp biopsy 63 22
5 kidney 2019 Whitlam [51] Melbourne, Australia prosp consec 55 13
6 heart 2011 Snyder [78] Stanford, USA retro consec 112 12
7 heart 2014 DeVlaminck [85] Stanford, USA prosp consec 65 n/a
8 heart 2016 Grskovic [17] CareDX, Brisb., USA retro consec 101 27
9 heart 2018 Ragalie [86] Wisconsin, USA retro biopsy 88 16
10 heart 2019 Macher [32] Sevilla, Spain prosp consec 30 13
11 liver 2017 Schütz [87] Gottingen, Germany prosp consec 107 17
12 liver 2019 Goh [50] Melbourne, Australia prosp consec 20 3
13 lung 2015 DeVlaminck [88] Stanford, USA prosp consec 51 n/a
14 lung 2018 Agbor-Enoh [89] Stanford, NIH, USA prosp consec 157 34
15 lung 2019 Agbor-Enoh [90] Stanford, NIH, USA prosp consec 106 n/a
* consecutive (consec): transplanted patients are consecutively included regardless of rejection; biopsy =
biopsy-linked: sampling parallels biopsy indicated by organ-failure. Legend: Original studies were included if the
cohort size equaled or exceeded n = 50 for kidney or n = 20 for other solid organs. Studies are listed according
to organ transplanted then according to year published. Abbreviations: n/a: not available; prosp: prospective;
retro: retrospective.
As an overall conclusion, significantly positive role was exclusively found across all organs for
plasma dd-cfDNA as allograft injury biomarker, no study was found concluding the lack of association.
In kidney transplant, the paramount prospective trial of Bloom et al. called “Circulating Donor-Derived
Cell-Free DNA in Blood for Diagnosing Active Rejection in Kidney Transplant Recipients” (DART)
had the strongest impact with subsequent positive decision about health insurance reimbursement in
the US. By using a cut-off value of 1.0% of dd-cfDNA these authors found that this biomarker had
stronger discriminating power between ABMR and absence of ABMR compared to cell mediated
rejection versus lack that of [56]. The biopsy-linked patient selection design allowed the enrichment of
patients with documented rejection episodes. Using essentially the same cohort additional aspects
were also examined by the same center such as the joint diagnostic characteristics of dd-cfDNA and
DSA [58] as well as biomarker performance details of dd-cfDNA with partial overlap with the original
study [57]. The relevant UCSF and Australian studies indeed represent independent confirmations,
albeit in smaller cohorts [18,51].
Heart transplant could be viewed as a pioneer of the field with an early study of a sizeable
cohort from Stanford taking advantage of a large biorepository also containing plasma, allowing the
selection more than a 100 sex-mismatched heart transplant cases [78] later confirmed in an independent
prospective cohort using the novel NGS-based technique [85]. Among the further confirmatory studies
a diagnostic method oriented study can be found by Grskovic et al. [17] as well as a pediatric heart
transplant cohort examined with proprietary diagnostic [86] and a Spanish study using an alternative,
technically less challenging diagnostic approach [32]. Regarding liver TX, besides an early case
report [91] and small prospective cohorts [50,92], a larger (n = 115) multicentric study demonstrated
significantly elevated dd-cfDNA levels in acute rejection compared to transplanted patients in stable
phase or those with hepatitis C infection [87]. Similarly, in the field of lung TX, besides a few smaller
studies, only the Stanford group was able to collect larger cohort after the initial study [85] with a
multicentric prospective trial indicating markedly elevated dd-cfDNA prior to graft-rejection proven
by biopsy [89] supplemented by a further study on essentially the same cohort [90].
Besides plasma, alternative test materials have also been used to monitor cfDNA after SOT.
Sigdel et al. observed rather large inter-patient variations of cfDNA in urine samples of a sizeable
(n = 61) kidney transplanted cohort with limited potential as a general diagnostic biomarker [93].
cfDNA was also measured in broncho-alveolar lavage (BAL) fluid after lung TX among 60 patients
along with the chemokine CXCL10 and the combination of these markers significantly predicted
allograft survival [52].
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The most important limitation of plasma dd-cfDNA monitoring is its lacking specificity for
rejection subtype, or specific histopathological alteration. However, due to its non-invasive character,
the potentially rapid laboratory turn-around time, the increasing accessibility and the continuously
decreasing cost, this approach may represent an early contributing diagnostic tool supplementing
available classical indicators.
6. Role of Microchimerism in Allogeneic Hematopoietic Stem Cell Transplantation
6.1. General Applications of Chimerism Monitoring in Allo-HSCT
Chimerism analysis (detection of the relative ratio of donor and recipient hematopoiesis) from
peripheral blood or bone marrow aspirates is a standard diagnostic procedure following allo-HSCT.
The replacement of recipient cells by those of the donor called complete donor chimerism is an
evidence for the successful engraftment and the reconstitution of hematopoiesis after allo-HSCT.
After myeloablative conditioning, residual recipient hematopoiesis may indicate graft failure and/or
persisting disease. Remaining or re-emerging recipient cells in the circulation, called mixed chimerism,
after transplantation is mostly associated with relapse in cases of hematopoietic malignancies, although
long term mixed chimerism without relapse has been described [94]. Persisting mixed chimerism is
reported to reduce the graft versus leukemia (GvL) effect of alloreactive donor T cells [95–97]. In case
of non-malignant disorders treated with non-myeloablative regimens, increasing mixed chimerism is
an indicator of graft rejection.
The dynamics of serial chimerism monitoring facilitates therapeutic interventions such
as modulation of immunosuppression, donor lymphocyte infusions, chemotherapy, or second
transplantation both in myeloablative and in non-myeloablative settings [95]. Early, individualized
interventions have the potential to balance between competing risks of graft failure, recurring disease,
and the potentially life-threatening graft versus host disease (GvHD).
Analysis of STRs by fragment analysis (FA) is the most widely accepted choice of method for
post-HSCT monitoring. Detailed recommendations are available for proper laboratory performance
of STR chimerism monitoring [9]. The major disadvantage of STR chimerism monitoring is its low
sensitivity (limit of detection: 1–5%). To circumvent this limitation, frequent monitoring (even weekly
before day 200 after allo-HSCT in pediatric acute lymphoblastic leukemia), performing the analysis
in subpopulations for the detection of lineage specific split chimerism are recommended, as acute
leukemia relapse can occur within a relatively short time frame [98].
Chimerism monitoring provides a surrogate biomarker for tumor-specific measurable residual
disease (MRD). Chimerism testing is suggested to be applied in combination with MRD monitoring
in malignant hematopoietic diseases [99,100]. In several clinical settings, MRD assay is not available
(due to the lack of identified disease specific somatic mutation) or clonal heterogeneity, in these cases
chimerism testing remains the only follow-up marker after allo-HSCT.
6.2. Relevance of Microchimerism Monitoring in Allo-HSCT
In recent years, the sensitive detection of MRD (reaching at least 0.1% or deeper limit of
detection) gained increasing attention, as patients with MRD-positive morphologic remission showed
similar outcome to patients with active disease [99,101]. Introducing sensitive techniques like qPCR
or dPCR enabled the reliable detection of microchimerism, which is defined as the presence of
recipient cells below 1% in the circulation. Initially, this sensitivity was not a requirement for
chimerism detection [102]. Earlier, the clinical utility of microchimerism detection after allo-HSCT was
controversial and limited [39]. Low levels of undulating microchimerism might have been detected for
years after allo-HSCT, which may not have been necessarily related to relapse. Studies focusing on
the potential advantages and the clinical utility of sensitive chimerism detection are summarized in
Table 3.
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Several papers indicated that the dynamics of microchimerism was more closely correlated with
relapse in acute leukemia. The reappearance of recipient DNA after complete donor chimerism is
a warning sign, and increasing recipient chimerism in two consecutive samples reliably forecast
relapse [28,103]. Stable or decreasing microchimerism levels might not indicate relapse. In acute
leukemia, several lines of evidence regarding allo-HSCT chimerism monitoring suggest that sensitive
methods (e.g., qPCR, dPCR) are superior compared to classic STR-fragment analysis in the prediction
of hematological relapses: (i) the ratio of detected/all relapses for DIP/qPCR was 70–100% vs. 13–44%
for STR/fragment analysis; (ii) the time difference in favor of DIP/qPCR vs. STR/fragment analysis was
26–90 days [13,27,34,44,96,104,105]. At the same time, the lack of recipient genotype in highly-sensitive
chimerism analysis excludes the possibility of relapses with high certainty [28,103]. Systemic infections,
especially virus infections, and acute GvHD were also variably associated with a slight increase
in host microchimerism. Leukemia relapse is usually associated with a rapid expansion of host
hematopoiesis [34,103,106].
Dynamics of chimerism also influence survival: complete donor and decreasing mixed
chimerism present favorably, while increasing and stable mixed chimerism have adverse prognostic
significance [105,107]. Recent studies indicated that not mixed chimerism, but also microchimerism after
allo-HSCT show adverse overall survival compared to complete donor chimerism (mixed chimerism
p < 0.0002; microchimerism p = 0.0201). The introduction of sensitive chimerism monitoring allows
early detection of recipient hematopoiesis, early intervention, and the decrease of patients proportions
with mixed chimerism above 1% (23% before and 15% after the introduction of sensitive chimerism
test) [94].
Mixed chimerism, and also microchimerism, were found to strongly correlate with
MRD-monitoring inasmuch, both biomarkers show similar time-course, when analyzed from the same
sample type [29,96,100]. As a conclusion, chimerism including microchimerism monitoring is a reliable
indicator of incipient acute myeloid leukemia (AML) relapse, especially in patients where no other
specific molecular marker is available, which might affect up to 50% of allo-HSCT cases [34]. In case
of chimerism monitoring, the lack of identifiable marker or subclonal heterogeneity do not alter the
results however, cytogenetic alterations in the malignant clone resulting in the loss of the recipient
allele carrying the respective marker may cause a false negative chimerism result.
Table 3. Potential advantages and clinical applicability of sensitive microchimerism detection in
allo-HSCT based selected papers.
First Author Year Country n Marker * Clinical Utility of Microchimerism Detection
Jiménez-
Velasco [13] 2005 Spain 61 VNTR, DIP
qPCR superior to FA in relapse prediction:
88% vs. 44%, 20 days prior FA;
rising host chimerism kinetics in relapse
Koldehoff
[105] 2006 Germany 269
STR, SNP,
FISH
XYSRY
qPCR superior to PAGE in relapse prediction:
90 days earlier; adverse overall survival in rising
kinetics;
SRY qPCR superior to XY FISH in relapse
prediction:
86% vs. 28%, 143 days prior relapse
Wiedermann
[107] 2010 Germany 75 DIP, SRY rising host chimerism kinetics in relapse
Chen
[27] 2011 Taiwan 126 STR, DIP qPCR superior to FA in relapse prediction
Horky [96] 2011 Czech 46 STR, DIP qPCR superior to FA in relapse prediction:87% vs. 39%, 26 days prior FA.
Bach [44] 2015 Germany 16 STR, DIP qPCR superior to FA in relapse prediction: 95days earlier
Jacque [28] 2015 France 85 DIP
stable qPCR complete chimerism = negative
predictor for relapse; rising host chimerism
kinetics in relapse
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Table 3. Cont.
First Author Year Country n Marker * Clinical Utility of Microchimerism Detection
Vicente [106] 2016 Brazil 41 DIP early rising host chimerism kinetics in relapse
Ahci [34] 2017 Germany 30 STR, DIP
qPCR superior to FA in relapse prediction:
100% vs. 38%, 6 months prior relapse;
rising or sustained host chimerism kinetics in
relapse
Waterhouse
[108] 2017 Germany 155 STR, SRY
dPCR superior to FA in relapse prediction: 90
days earlier
Cechova [94] 2018 Czech 474 STR, DIP adverse overall survival in microchimerismcompared to complete donor chimerism
Sellmann
[103] 2018 Germany 71 DIP
stable qPCR complete chimerism = negative
predictor for relapse; rising host chimerism
positive predictor for relapse
Waterhouse
[29] 2018 Germany 70 DIP, MRD similar kinetics for chimerism and MRD
Tyler
[37] 2019 USA 230 STR, DIP
combined STR-FA and DIP-qPCR in diagnostic
algorithm;
qPCR is more sensitive than FA
Valero-Garcia
[35] 2019 Spain 28 DIP dPCR superior to qPCR in relapse prediction
* STR, VNTR markers were tested with FA or PAGE; DIP, SNP, and SRY were tested with qPCR or dPCR. Legend:
Original in extenso studies were included if clinical outcome of allo-HSCT (relapse, survival measures) was indicated
in connection with chimerism levels below 1%. Studies are listed according to year published. Abbreviations: DIP:
deletion-insertion polymorphism; FA: fragment analysis; FISH: fluorescence in situ hybridization; MRD: measurable
residual disease; PAGE: poly-acrilamid gel-electrophoresis; qPCR: quantitative polymerase chain reaction; SNP:
single nucleotide polymorphism; SRY: sex determining region Y; STR: short tandem repeat; VNTR: variable number
tandem repeat.
6.3. Special Applications of Microchimerism Monitoring in Cellular Therapies
In hematology practice, special cellular therapies are becoming more and more frequent treatment
options: examples are ‘microtransplantation’ in elderly AML patients, natural killer (NK) cell infusion
or third-party donor antigen-specific T-cell infusions (virus specific T cells, VST) [109]. As these
allogeneic cellular therapies are not intended to achieve durable engraftment, they frequently result in
microchimerism not detectable with standard STR-based monitoring.
In a randomized, multicenter study of elderly AML patients, induction chemotherapy in
combination with mobilized HLA-mismatched donor cells without GvHD-prophylaxis improved
response rates with a low rate of mixed or complete donor chimerism (5/185) and severe acute GvHD
(2/185). Microchimerism was detectable in 31% (8/26) sex-mismatched, informative transplants by
SRY-qPCR (with up to 10 months follow-up) [110]. Microtransplantation was found to be inferior to
HLA-matched sibling donor transplantation in allo-HSCT eligible patients for intermediate/high-risk
AML in complete remission [111], but a case report described its utility as salvage therapy in refractory
AML [112]. Haploidentical natural killer cell therapy is a safe and feasible therapeutic option in pediatric
relapsed or refractory leukemia [113]. Adoptive transfer of VST cells aim to restore T-cell immunity
and cure allo-HSCT patients with refractory, life-threatening viral infections like cytomegalovirus,
Epstein–Barr virus, or adenovirus [114]. Kliman et al. described an ultrasensitive dPCR method capable
to detect donor microchimerism after cellular therapies such as microtransplantation or VST [36].
6.4. Cell-Free DNA Chimerism Following Allo-HSCT
Plasma cfDNA markers as diagnostic applications have been intensively studied in the context of
prenatal screening, solid tumors and SOT. The clinical usefulness of chimerism testing from plasma
cfDNA in allo-HSCT has been sparsely reported. Initially, sex-mismatched allo-HSCT patients were
screened to reveal the main cellular origin of plasma circulating cfDNA. Y-chromosome specific cfDNA
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was detected in plasma with a median of 6.9% in male patients with female donors, indicating the
hematopoietic compartment as the main origin of plasma cfDNA [2].
Plasma cfDNA was found to be more sensitive than cellular chimerism in detecting relapse in
leukemia patients with complete donor chimerism in polymorphonuclear cells. All patients with
clinical relapse (16/84, 19%) had more than 10% of recipient cfDNA in the plasma. Altogether 60% of
patients displayed various levels of mixed chimerism in plasma, including an additional 16 patients
with >10% mixed chimerism level and without clinical relapse [115].
A further study indicated that mixed chimerism was detectable in cfDNA in a higher percentage
of samples than in peripheral blood cells after allo-HSCT. Interestingly, plasma cfDNA-based
microchimerism was capable of detecting isolated extramedullar relapses (central nervous system,
n = 3), when in peripheral blood cells complete donor chimerism was observed [116]. Recipient derived
cfDNA was elevated not only in relapse, but also in transplant related complications, especially in
acute GvHD (aGvHD). The improvement of aGvHD symptoms during therapy coincided with the
decrease in recipient cfDNA, in contrast, the lack of aGvHD amelioration was associated with stable
or increasing levels of recipient cfDNA. This association suggested that recipient cell disruption in
GvHD target organs can be a source of cfDNA. No correlation was found between mean recipient
cfDNA percentage and aGvHD severity (grade I–II compared to grade III–IV), but organ specific
involvements have not been described. Chronic GvHD (cGvHD) did not show an association with
plasma cfDNA-based mixed chimerism in affected patients [116]. Plasma cell free mitochondrial
DNA (mtDNA) was reported to be elevated in allo-HSCT patients. As an endogenous inflammatory
signal, cell free mtDNA may activate a B-cell subset responsible for extensive cGvHD: the onset of
cGvHD was accompanied with significantly elevated levels of plasma cell free mtDNA in patients
with cGvHD [117].
7. Future Perspectives
In the context of SOT, additional independent, sufficiently large cohort studies are needed to
further confirm the diagnostic value of microchimerism characterized by dd-cfDNA proportion in
plasma. A further goal of these studies can be the targeting patients with subclinical graft damage for
which currently the only diagnostic tool is the invasive organ biopsy. Applicability of dd-cfDNA based
microchimerism detection as valuable information in the clinical decision-making process regarding
actual immunosuppression should also be tested in a prospective setting. Routine application and
comparisons of alternative detection techniques may also be attractive for future research since a
considerable number of transplantation diagnostic facilities may not have access to the most advanced
NGS-based determinations.
Although it is not widely accepted yet, monitoring of recipient cfDNA dynamics after allo-HSCT
may be a valuable diagnostic tool to detect relapses at earlier time points, with special emphasis
on extramedullary sites. Additionally, it can be utilized as a non-invasive biomarker for aGvHD
activity. Further studies involving larger patient cohorts, as well as applying more sensitive methods
than STR are necessary to address existing uncertainties regarding cfDNA chimerism testing in the
allo-HSCT field.
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